AMRX
Amneal Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$21.51Close
$10.00 – $21.5152-week range
Nov 3, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 93 · stronger than 93% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Tight base near its pivot pullbacks 12% → 10%; 3.5% above its $20.78 pivot
- Earnings growing EPS +153% year on year
Cautions
- Extended 4.2 ATR above its 50-day average
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 5.5%
price change
1mo
up 6.8%
price change
12-month return
up 115%
market up 11% ·
its own up 95%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 8%
year on year
EPS growth
up 153%
latest quarter · -250 pts
Sales growth
up 10%
latest quarter · +6 pts
ROE
—
return on equity
Free cash margin
up 9%
$269.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
5.8×
Interest cover
—EBIT / interest
Trade setup
ATR%
2.9%
$0.63 a day · 2×ATR $20.24
RS
93 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.47
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Contractions
2
12% → 10%
Pivot
$20.78
3.5% above
Volume dry-up
1.4×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$70.8M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Heavily indebted Net debt is 5.8 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported
Jul 30, 2026
Financials
- Gross 37%
- Net 2%
- Free cash 9%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B |
| Gross margin | 32% | 37% | 35% | 34% | 37% | 37% |
| Operating income | $91.2M | $152.7M | -$94.9M | $204.4M | $249.3M | $394.1M |
| Net income | $67.8M | $13.2M | -$270.6M | -$84.0M | -$116.9M | $72.1M |
| Net margin | 3% | 1% | -12% | -4% | -4% | 2% |
| Earnings per share | $0.46 | $0.09 | -$1.79 | -$0.48 | -$0.38 | $0.22 |
| Free cash flow | $322.6M | $194.1M | $18.7M | $302.4M | $243.2M | $269.9M |
| Free cash margin | 16% | 9% | 1% | 13% | 9% | 9% |
| Cash | $341.4M | $247.8M | $26.0M | $91.5M | $110.6M | $282.0M |
| Long-term debt | $2.7B | $2.7B | $2.6B | $2.4B | $2.2B | $2.6B |
| Shareholders' equity | $303.3M | $360.3M | $298.4M | $19.8M | -$109.3M | -$70.8M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 10, 2026 | Material agreement · Acquisition or disposal · New obligation · Unregistered share sale · Regulation FD ↗ |
| Aug 3, 2026 | Material agreement ↗ |
| Jul 31, 2026 | Shareholder vote ↗ |
| Jul 30, 2026 | Results · Regulation FD ↗ |
| May 7, 2026 | Results ↗ |
| May 7, 2026 | Shareholder vote ↗ |
| Apr 22, 2026 | Material agreement · Results · Unregistered share sale · Regulation FD ↗ |
| Feb 27, 2026 | Results · Regulation FD ↗ |
| Feb 3, 2026 | Material agreement · New obligation ↗ |
| Jan 28, 2026 | Other events ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Oct 30, 2025 | Results · Regulation FD ↗ |